Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279976 | 0.79 | KMT2A (0.67) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL2759030 | 0.77 | HIF1A (0.72) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL11818229 | 0.77 | HPGD (0.76) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL12195828 | 0.75 | NAMPT (0.43) | RAB9ANPC1POLBKMT2AMEN1 | |
| SCHEMBL17788542 | 0.75 | HPGD (0.69) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL11918653 | 0.74 | KMT2A (0.86) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL279957 | 0.74 | KMT2A (0.86) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL14395933 | 0.74 | KMT2A (0.67) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL15888632 | 0.74 | HPGD (0.67) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL12942542 | 0.73 | HPGD (0.64) | HPGDSMN1; SMN2RAB9ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9044389-B2 | Isoxazoline derivatives as pesticides | NOVARTIS TIERGESUNDHEIT AG (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20140120147-A1 | ISOXAZOLINE DERIVATIVES AS PESTICIDES | NOVARTIS AG (CH) | 2014-05-01 | — | — | US | disclosed |
| US-8653116-B2 | Isoxazoline derivatives as pesticides | NOVARTIS AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-20130131053-A1 | ISOXAZOLINE DERIVATIVES AS PESTICIDES | NOVARTIS TIERGESUNDHEIT AG (CH) | 2013-05-23 | — | — | US | disclosed |
| US-8383659-B2 | Isoxazoline derivatives as pesticides | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20110245239-A1 | ORGANIC COMPOUNDS | ELANCO TIERGESUNDHEIT AG (CH) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131053-A1 | ISOXAZOLINE DERIVATIVES AS PESTICIDES | CYP3A7, ACHE, CYP4X1 | HPGD 1492/4885SMN1; SMN2 3187/4885RAB9A 1900/4885 |
| US-20140120147-A1 | ISOXAZOLINE DERIVATIVES AS PESTICIDES | CYP3A7, ACHE, CYP4X1 | HPGD 1492/4885SMN1; SMN2 3187/4885RAB9A 1900/4885 |
| US-20110245239-A1 | ORGANIC COMPOUNDS | ACHE, VDAC1, VDAC2 | HPGD 1666/4885SMN1; SMN2 648/4885RAB9A 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.